In a large implementation study of HER2 testing involving 192 tumor samples from 180 patients with endometrial carcinoma, HER2 positivity was detected in 28% of all cases and in 30% of tumors with aberrant p53, confirming that a substantial proportion of patients may be eligible for targeted anti-HER2 therapy [18]. Here, TP53 is linked to neoplasm.